News, Publications & Presentations 

Immodulon, the immuno-oncology company, is pleased to announce that Ruslan Croitoru (MD MSc (Oxon) MFPM) will be joining the Immodulon Core Management Team as the Chief Medical Officer. Ruslan is a cardiologist. He gained his medical degree in Moldova, where he...

Immodulon, the immuno-oncology company, is pleased to announce that Maikel Dijkstal will be joining the Immodulon Core Management Team as CMC Programme Manager with immediate effect. Based in The Netherlands, Maikel has spent much of his working career in...

Immodulon, the immuno-oncology company, announces that their IMM-101-015 Phase II clinical trial has commenced. The open-label clinical study will assess the safety and efficacy of the combination of IMM-101 with Nivolumab, an immune checkpoint inhibitor, in 26...

Immodulon, the immuno-oncology company, is pleased to announce that Dr Kevin Bilyard, who served as CEO of Immodulon from 2008 to 2016 and more recently been an advisor to the company's Board of Directors, has accepted a position on the Immodulon Board. His career...

Immodulon, the immuno-oncology company, today announces the appointment of Dr Jaap Kampinga, current Chief Scientific Officer (CSO), as Chief Executive Officer (CEO) effective from 1st July 2018. Dr Kampinga is a medical doctor and immunologist and has considerable...

Immodulon, the immuno-oncology company, is pleased to announce the appointment of Dr Jerome Zeldis to the Immodulon Board who has also been offered the position of Chairman of the Scientific Advisory Board. Jerry joins the company from Celgene where he held the...

Immodulon, the immuno-oncology company, is pleased to announce the appointment of Dr Jaap Kampinga as its Chief Scientific Officer. He will work closely with COO Graham Burton and the Immodulon Board to realise the company’s potential as leaders in cancer...

In IMAGE-1, a phase II proof-of-concept study recruiting 110 patients with locally advanced or metastatic pancreatic cancer, patients were randomized to receive IMM‑101 + gemcitabine or gemcitabine alone. This study was designed to provide indicative rather than...

Immodulon, the immuno-oncology company, is pleased to announce the appointment of Andy Clarke as its Non- Executive Chairman. He will be joined by Dr. Graham Burton as Chief Operating Officer. Andy has over 25 years’ experience of driving performance improvements in...

Immodulon attended the 15th International Congress on Targeted Anticancer Therapies (TAT), which took place from the 6th- 8th March in Paris. TAT congresses are annual meetings on new molecular targets and innovative cancer therapeutics in the early phases of clinical...

The Office of Naval Research, which is part of the US Department of Defence, has awarded a grant of up to two years of support to Professor Stefan Reber (Laboratory for Molecular Psychosomatics, University of Ulm, Germany) for his work on the promotion of stress...

Immodulon attended the 3rd annual Immuno‑Oncology 360° event taking place February 1st - 3rd, 2017 in New York. Immuno-Oncology 360° is a global conference attracting national and international experts and thought leaders from large pharmaceuticals and...

A CU Boulder study led by Immodulon Scientific Advisory Board member Dr Christopher Lowry showing that injecting beneficial bacteria into mice can make them more resilient to stress has been named among the “top 10 advancements and...

Data from an ongoing collaboration between the laboratory of Prof. Andrew MacDonald at Manchester Collaborative Centre for Inflammation Research (University of Manchester, Manchester, UK) and Immodulon Therapeutics shedding light on adaptive immune responses initiated...

Data from an ongoing collaboration between Immodulon Therapeutics and the laboratory of Prof. Andrew MacDonald at Manchester Collaborative Centre for Inflammation Research (University of Manchester, Manchester UK) on the effects of combination treatment of IMM‑101 (a...

It is with great sadness that Immodulon announces the passing of Professor John Grange, one of the founding members of Immodulon. John played a crucial role in establishing the company for which the entire Immodulon team will always be extremely grateful. His death is...

In IMAGE-1, a phase II proof-of-concept study recruiting 110 patients with locally advanced or metastatic pancreatic cancer, patients were randomized to receive IMM‑101 + gemcitabine or gemcitabine alone. This study was designed to provide indicative rather than...

Further data from an ongoing collaboration between the laboratory of Prof. Andrew MacDonald at Manchester Collaborative Centre for Inflammation Research (University of Manchester, Manchester, UK) and Immodulon Therapeutics on the effects of IMM-101 (a heat-killed...

Results from pre-clinical research conducted at the University of Colorado Boulder in the USA led by Dr Chris Lowry, as part of an agreement with Immodulon to test Mycobacterium vaccae NCTC11659 in a variety of laboratory models of mental health disorders. Full title:...

In this review, Immodulon in collaboration with Myriad Rule Based Medicine (USA) describes the TruCulture® system. This technology applied to small whole blood sample permits investigation of immunological activity following immune stimulation resulting in synthesis...